Danaher Corporation $DHR Shares Sold by Maverick Capital Ltd.

Maverick Capital Ltd. decreased its holdings in shares of Danaher Corporation (NYSE:DHR) by 46.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 372,126 shares of the conglomerate’s stock after selling 326,614 shares during the quarter. Danaher comprises approximately 1.1% of Maverick Capital Ltd.’s holdings, making the stock its 26th biggest holding. Maverick Capital Ltd.’s holdings in Danaher were worth $73,510,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. White Pine Capital LLC raised its position in Danaher by 1.4% in the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after purchasing an additional 49 shares during the period. Boyd Watterson Asset Management LLC OH grew its stake in shares of Danaher by 2.1% in the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after buying an additional 51 shares in the last quarter. Worth Financial Advisory Group LLC raised its holdings in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after buying an additional 53 shares during the period. Bruce G. Allen Investments LLC raised its holdings in shares of Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after buying an additional 54 shares during the period. Finally, Texas Bank & Trust Co lifted its position in Danaher by 1.6% during the 2nd quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after acquiring an additional 55 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of Danaher stock opened at $232.36 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The firm’s 50-day simple moving average is $218.28 and its 200-day simple moving average is $205.38. The firm has a market cap of $164.13 billion, a PE ratio of 47.91, a price-to-earnings-growth ratio of 4.47 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the company earned $1.71 earnings per share. Danaher’s quarterly revenue was up 4.4% on a year-over-year basis. Equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the sale, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This represents a 13.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 over the last 90 days. 11.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on DHR shares. The Goldman Sachs Group initiated coverage on shares of Danaher in a research report on Tuesday. They issued a “buy” rating and a $265.00 price objective for the company. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Wells Fargo & Company reaffirmed a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Bank of America cut their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research note on Wednesday, October 8th. Twenty-one analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $246.79.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.